Dishman Carbogen Amcis Net Revenue stands at Rs. 541 Crores for Q1 FY23
Ahmedabad (Gujarat) [India], August 12: Dishman Carbogen Amcis Ltd, a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies, announces their first quarter (Q1FY23) results.
Financial performance
Consolidated Q1FY23 review
Net revenue was Rs. 5,406mn for Q1 FY23 as compared to Rs. 5,507mn in the corresponding period of the previous year
EBITDA stood at Rs. 904 mn for Q1 FY23 as compared to Rs. 1,006 mn during the corresponding period of previous year
EBITDA Margin at 16.7% for Q1 FY23 as against 18.3% in Q1 FY22
Net Profit stood at Rs. 40 mn for Q1 FY23 as compared to Rs. 160 mn in the cor...